Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
Lan Wei,Yuanyuan Han,Chao Tu
DOI: https://doi.org/10.2147/DMSO.S392888
2023-01-12
Abstract:Lan Wei, 1 Yuanyuan Han, 2 Chao Tu 1 1 Department of Internal Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, People's Republic of China; 2 Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, People's Republic of China Correspondence: Chao Tu, Department of Internal Medicine, The Third Affiliated Hospital of Soochow University, 185 Juqian Road, Changzhou, 213000, People's Republic of China, Email Diabetic kidney disease (DKD) affects an estimated 20– 40% of type 2 diabetes patients and is among the most prevalent microvascular complications in this patient population, contributing to high morbidity and mortality rates. Currently, changes in albuminuria status are thought to be a primary indicator of the onset or progression of DKD, yet progressive nephropathy and renal impairment can occur in certain diabetic individuals who exhibit normal urinary albumin levels, emphasizing the lack of sensitivity and specificity associated with the use of albuminuria as a biomarker for detecting diabetic kidney disease and predicting DKD risk. According to the study, a non-invasive method for early detection or prediction of DKD may involve combining proteomic analytical techniques such second generation sequencing, mass spectrometry, two-dimensional gel electrophoresis, and other advanced system biology algorithms. Another category of proteins of relevance may now be provided by renal tissue biomarkers. The establishment of reliable proteomic biomarkers of DKD represents a novel approach to improving the diagnosis, prognostic evaluation, and treatment of affected patients. In the present review, a series of protein biomarkers that have been characterized to date are discussed, offering a theoretical foundation for future efforts to aid patients suffering from this debilitating microvascular complication. Keywords: diabetic kidney disease, proteomics, diagnostic biomarkers, therapeutic targets Diabetic kidney disease (DKD) is a common microvascular complication that impacts 20–40% of individuals diagnosed with type 2 diabetes, resulting in high rates of morbidity and mortality. DKD is diagnosed based on the detection of persistent proteinuria, an albumin creatinine ratio greater than 30 mg/g creatinine, a reduction in the estimated glomerular filtration rate (eGFR), and the progressive deterioration of kidney function. 1,2 Persistent hyperglycemia in individuals with diabetes can drive the increased synthesis of extracellular matrix (ECM) proteins, enhanced cell proliferation, and the dysfunction of endothelial cells together with tubular atrophy, interstitial fibrosis, and the thickening of the glomerular and tubular basement membrane as a consequent of inflammation, oxidative stress, and advanced glycation end product (AGE) production. 3 DKD development is further driven by the increased accumulation of protein within the renal extracellular matrix, the expansion of the mesangial matrix, glomerular hyperfiltration, tubulointerstitial fibrosis, and the aggravated thickening of the glomerular basement membrane. Injury to glomerular podocytes can also contribute to DKD incidence. 1 Both a reduction in eGFR and albuminuria are considered relatively non-specific biomarkers of DKD given that they are also altered in the context of many other chronic glomerular diseases, with 60% of nephron function already being absent with eGFR values falling to the threshold of 60 mL/min/1.73 m 2 . 4 Given that DKD is a prevalent cause of end-stage renal disease (ESRD), it is critical that reliable biomarkers that can guide the diagnosis and treatment of this condition be defined. Both urinary albumin (UALB) and β2-microglobulin (Uβ2m) have been leveraged as biomarkers of glomerular and tubular injury, 5 yet these levels and eGFR changes are only evident after substantial glomerular damage has taken place. However, many patients exhibit histopathological alterations in renal structures prior to the onset of microalbuminuria. 6 While these changes can be detected through renal biopsy, enabling the more robust diagnosis and monitoring of affected patients, the utility of this approach is limited by the inherent invasivity of biopsy procedures. As such, there is a pressing need for the establishment of new, non-invasive biomarkers that can gauge the risk of future DKD onset or detect this disease while in its earliest stages. Certain urinary and plasma protein biomarkers have been linked to the pathophysiology of many forms of renal disease, and some of these biomarkers have even been successfully implemented in clinical settings. The kidneys directly pr -Abstract Truncated-
endocrinology & metabolism